Home » Stocks » NTUS

Natus Medical Incorporated (NTUS)

Stock Price: $27.08 USD 1.38 (5.37%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $28.40 +1.32 (4.87%) Jan 19, 7:31 PM
Market Cap 917.13M
Revenue (ttm) 428.38M
Net Income (ttm) -20.14M
Shares Out 33.83M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $27.08
Previous Close $25.70
Change ($) 1.38
Change (%) 5.37%
Day's Open 26.04
Day's Range 25.57 - 27.17
Day's Volume 229,433
52-Week Range 16.65 - 33.73

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

PLEASANTON, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnos...

GlobeNewsWire - 2 weeks ago

PLEASANTON, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagn...

GlobeNewsWire - 1 month ago

PLEASANTON, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagno...

GlobeNewsWire - 1 month ago

PLEASANTON, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnos...

Zacks Investment Research - 2 months ago

Natus Medical (NTUS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Investment Research - 2 months ago

Natus Medical (NTUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 2 months ago

Natus Medical Incorporated (NTUS) CEO Jonathan Kennedy on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Natus Medical (NTUS) delivered earnings and revenue surprises of 800.00% and 8.90%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

PLEASANTON, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnos...

Zacks Investment Research - 2 months ago

Natus Medical (NTUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 3 months ago

PLEASANTON, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagn...

GlobeNewsWire - 4 months ago

PLEASANTON, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the dia...

Seeking Alpha - 5 months ago

Natus Medical Incorporated (NTUS) CEO Jonathan Kennedy on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Natus Medical (NTUS) delivered earnings and revenue surprises of -360.00% and -13.67%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

PLEASANTON, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagn...

Zacks Investment Research - 5 months ago

Natus Medical (NTUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

PLEASANTON, Calif., June 11, 2020 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diag...

The Motley Fool - 7 months ago

What should investors think of this infant care and neurology specialist?

GlobeNewsWire - 8 months ago

Partnership to advance the development and distribution of innovative AutoSCORE algorithm Partnership to advance the development and distribution of innovative AutoSCORE algorithm

GlobeNewsWire - 9 months ago

PLEASANTON, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diag...

GlobeNewsWire - 10 months ago

Another key partner joins the Otocloud community, expanding the reach even further.

GlobeNewsWire - 1 year ago

PLEASANTON, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diag...

About NTUS

Natus Medical Incorporated provides medical device solutions focusing on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and services used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and n... [Read more...]

Industry
Medical Devices
Founded
1987
CEO
Jonathan Kennedy
Employees
1,484
Stock Exchange
NASDAQ
Ticker Symbol
NTUS
Full Company Profile

Financial Performance

In 2019, Natus Medical's revenue was $495.18 million, a decrease of -6.73% compared to the previous year's $530.89 million. Losses were -$15.67 million, -31.67% less than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Natus Medical is 36.00, which is an increase of 32.94% from the latest price.

Price Target
$36.00
(32.94% upside)